Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | IL1RN | P18510 | 2/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14419537 | 0.89 | MEN1 (0.40) | CYP2A6PARP10PARP11PIM1CSNK1A1 | |
| SCHEMBL2066611 | 0.86 | CYP2A6 (0.43) | CYP2A6PARP10PARP11PIM1CSNK1A1 | |
| SCHEMBL1662187 | 0.84 | CYP2A6 (0.52) | CYP2A6PARP10PARP11PIM1CSNK1A1 | |
| SCHEMBL29385577 | 0.84 | CYP2A6 (0.52) | CYP2A6PARP10PARP11PIM1CSNK1A1 | |
| SCHEMBL29907208 | 0.83 | CYP1A2 (0.52) | CYP2A6PARP10PARP11PIM1CSNK1A1 | |
| SCHEMBL2327414 | 0.83 | CYP1A2 (0.52) | CYP2A6PARP10PARP11PIM1CSNK1A1 | |
| SCHEMBL206466 | 0.80 | CYP2A6 (0.52) | CYP2A6CYP1A2IL1RNERAP2ERAP1 | |
| SCHEMBL3976079 | 0.78 | — | — | |
| SCHEMBL7935846 | 0.78 | CYP2A6 (0.46) | CYP2A6CYP1A2MEN1KMT2ATRPV1 | |
| SCHEMBL5535806 | 0.78 | CYP2A6 (0.54) | CYP2A6CYP1A2IL1RNERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4244050-A | — | — | None | — | — | JP | disclosed |
| US-20250250246-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-08-07 | — | — | US | disclosed |
| US-12286414-B2 | Method for producing heterocyclidene acetamide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-04-29 | — | — | US | disclosed |
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| CN-115594669-B | Parallel ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-118812481-A | Process for producing heterocyclylacetamide derivative | 持田制药株式会社 | 2024-10-22 | — | — | CN | disclosed |
| EP-4410989-A2 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4019485-B1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-114206847-B | Process for producing heterocyclylacetamide derivative | 持田制药株式会社 | 2024-07-16 | — | — | CN | disclosed |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-4968679-A | DISORDERS OF CENTRAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM OR INTESTINAL TRACT | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| CN-1046528-A | As the new naphthalane base-3H-1 of antihyperglycemic agents, 2,3,5-oxygen thia diazole 2-oxide compound | AMERICAN HOME PROD (US) | 1990-10-31 | — | — | CN | disclosed |
| US-4966975-A | Processes for the preparation of novel naphthalenylmethyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents | AMERICAN HOME PRODUCT | 1990-10-30 | — | — | US | disclosed |
| EP-0393941-A1 | Naphthalene derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-10-24 | — | — | EP | disclosed |
| EP-0385658-A1 | Ring-substituted 2-amino 1,2,3,4-tetra-hydronaphthalenes and 3-aminochromanes | ELI LILLY AND COMPANY (US) | 1990-09-05 | — | — | EP | disclosed |
| CN-1045099-A | Ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes | LILLY CO ELI (US) | 1990-09-05 | — | — | CN | disclosed |
| US-4897405-A | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-01-30 | — | — | US | disclosed |
| US-4873262-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, CARDIIOVASCULAR SYSTEM OR INTESTINAL TRACT | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-10 | — | — | US | disclosed |
| CN-87101285-A | 8-replaces-2-amino-1,2,3, the 4-tetrahydro-bitter edible plant | — | 1988-08-17 | — | — | CN | disclosed |
| EP-0272534-A2 | 8-substituted 2-aminotetralins | BAYER AG (DE) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | GLI1, GLI2, SHH | CYP2A6 4734/4885PARP10 1758/4885PARP11 913/4885 |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | CYP2A6 2069/4885PARP10 3938/4885PARP11 4308/4885 |
| US-12286414-B2 | Method for producing heterocyclidene acetamide derivative | COASY, NAAA, AADAC | CYP2A6 217/4885PARP10 1626/4885PARP11 1282/4885 |
| US-20250250246-A1 | METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | COASY, NAAA, AADAC | CYP2A6 217/4885PARP10 1626/4885PARP11 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.